Clinical trial NCT01151605: The Suppression of Toll Like Receptors by Insulin
Official title: The Suppression of Toll Like Receptors by Insulin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Insulin Resistance
Lead sponsor: University at Buffalo
Sponsor class: OTHER
Collaborators: name: American Diabetes Association
First posted: 2010-06-28
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will help us understand the possible beneficial effects of insulin in inflammation. Inflamamtion is considered to be the cause of atherosclerosis and heart disease.

Detailed description: Obesity and type 2 diabetes are major health problems in the United States and the world. Both conditions are characterized by increased inflammation and oxidative stress and are associated with increased risk of cardiovascular disease.

Our previous work shows that insulin exerts a prompt and powerful anti-inflammatory effect, on circulating blood cells and in plasma in healthy subjects and in critically ill patients.

Toll like receptors (TLRs) recognize bacterial and viral products like endotoxin and viruses and are major determinants of the inflammatory response against foreign pathogens. In view of the recent data showing that TLRs recognize a range of molecules and proteins that are not of pathogenic source like saturated lipids and that TLRs are involved in the pathogenesis of atherosclerosis which leads to cardiovascular disease and insulin resistance which leads to type 2 diabetes (DM) we hypothesized that insulin infusion suppresses TLRs expression.

Our preliminary data show that insulin infusion for 4 hours reduces the levels of many TLRs and thus might protect from inflammation induced conditions We therefore propose to investigate, in more detail, the effect of infusing different doses of insulin on TLRs mRNA and protein levels and its activity in obese and DM subjects over a longer infusion period and a larger number of subjects in circulating white blood cells and in fat tissue. Also we will be comparing the baseline levels of TLRs and TLRs related proteins as well as their modulation by insulin between normal, obese and DM subjects.

Eligibility criteria: INCLUSION CRITERIA

Lean Group:

1. Age: 20 to 65 years of age inclusive
2. Sex: male or female
3. Normal fasting plasma glucose (65-100 mg/dl)
4. Normal BMI (20-25)

Obese Group:

1. Age: 20 to 65 years of age inclusive
2. Sex: male or female
3. Normal fasting plasma glucose (65-100 mg/dl)
4. BMI\> 30

DM Group:

1. Type 2 Diabetes Mellitus
2. Age: 20 to 65 years of age inclusive
3. Sex: male or female
4. BMI \>30
5. Hba1c \< 8%
6. If on statins, angiotensin converting enzyme inhibitor, angiotensin receptor blocker or low dose aspirin, should be on a stable dose for one month.

EXCLUSION CRITERIA

1. Pregnancy
2. Congestive heart failure
3. Heart Rate \<50 beats /minute
4. Sick Sinus Syndrome
5. Second or third degree heart block
6. Blood pressure \<80 mm systolic or \> 160/100 mmHg
7. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery or coronary angioplasty) in the previous three months
8. Hepatic disease (transaminase \> 3 times normal)
9. Renal impairment (serum creatinine \> 1.5)
10. History of drug or alcohol abuse within past one year
11. Participation in any other concurrent clinical trial
12. Potassium (K+) values \<3.5 meq/l to \> 5.5 meq/l)
13. Any other life-threatening, non-cardiac disease
14. Use of an investigational agent or therapeutic regimen within 30 days of study
15. Type 2 diabetics on thiazolidinediones and/ or insulin
16. Subjects on steroids, NSAIDS or antioxidants
17. Patients taking exenatide or sitaglipin or loop diuretics
18. Anemia (Hemoglobin level less than 12gm/dl in females and 13gm/dl in males) 19)Allergy to lidocaine

Primary outcomes:
measure: The Suppression of Toll Like receptors by Insulin
timeFrame: 24 hours
Secondary outcomes:
measure: TLR expression
timeFrame: 0 hours
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: Millard Fillmore Gates Hospital
state: New York
Study officials:
affiliation: The Research foundation of SUNY at Buffalo
name: Paresh Dandona, MBBS
role: PRINCIPAL_INVESTIGATOR
References: